IJU case reports · 2026
Early Recognition of Immune-Related Hepatitis During Avelumab Maintenance Therapy for Urothelial Carcinoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Iwama Yuka, Sano Tomoyasu, Sano Yuta, Kimura Tomokazu, Naito Yushi, Inoue Satoshi, Matsuo Kazuna, Ishida Shohei, Matsukawa Yoshihisa, Akamatsu Shusuke
Аннотация
INTRODUCTION: Avelumab is recommended as maintenance therapy for advanced urothelial carcinoma after platinum chemotherapy; however, immune-related adverse events can be severe and refractory.
CASE PRESENTATION: A 79-year-old male developed immune-related hepatitis during avelumab maintenance therapy following gemcitabine plus carboplatin for metastatic recurrent urothelial carcinoma. Despite discontinuation of avelumab and treatment with high-dose corticosteroids, mycophenolate mofetil, and plasma exchange, liver failure progressed, leading to death on day 106.
CONCLUSION: Hepatic irAEs during avelumab therapy are rare but potentially fatal. Early recognition and aggressive multidisciplinary management are essential to improve outcomes.
CASE PRESENTATION: A 79-year-old male developed immune-related hepatitis during avelumab maintenance therapy following gemcitabine plus carboplatin for metastatic recurrent urothelial carcinoma. Despite discontinuation of avelumab and treatment with high-dose corticosteroids, mycophenolate mofetil, and plasma exchange, liver failure progressed, leading to death on day 106.
CONCLUSION: Hepatic irAEs during avelumab therapy are rare but potentially fatal. Early recognition and aggressive multidisciplinary management are essential to improve outcomes.